Asia-Pacific Opioid Induced Constipation Drug Market Forecast 2017-2025

Publisher Name :
Date: 01-Aug-2017
No. of pages: 54

Key Findings

The Asia-Pacific Opioid Constipation Drug market is estimated to grow at a CAGR of 5.07% during the forecast period of 2017-2025. The market worth is expected to increase from $233 million in 2016 and reach $361.88 million by 2025. The ease in the availability of new and improved drugs and the growing geriatric population are currently driving the Asian Market.

Market Insights

The Asian market can be classified on the basis of drug type and prescription type. The drug type is further classified into naloxegol, lubiprostone, and methyl naltrexone bromide and some pipeline drugs such as naldemedine, alvimopan, dolcanatide and elobixibat. The prescription type is classified into generic and branded prescribed drugs and over the counter drugs. A large number of considerations while using opioids is a major challenge currently faced by the market.

Competitive Insights

Some of the major players in the market are

• Daiichi Sankyo Co Ltd

• Pfizer

• Shionogi & Co., Ltd.

• Allergan Plc

• Nektar Therapeutics

• Mundipharma International Limited

• Ono Pharmaceutical Co., Ltd.

• Takeda Pharmaceutical Company Limited

• Cosmo Pharmaceuticals Sa

• Daewoong Pharmaceutical Co

Asia-Pacific Opioid Induced Constipation Drug Market Forecast 2017-2025

Table of Contents

1. Research Scope
1.1. Study Goals
1.2. Scope of the Market Study
1.3. Who Will Find This Report Useful?
1.4. Study and Forecasting Years
2. Research Methodology
2.1. Sources of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. . Top Down Approach
2.3. Bottom Up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
4. Market Overview
4.1. Market Definition
4.2. Key Market Insights
4.3. Attractive Investment Scenario
4.4. Positioning of Key Cic Drugs Manufacturers In the Market
4.5. Market Drivers
4.5.1. Rising Use of Opioid
4.5.2. Increasing Geriatric Population
4.5.3. Easy Availability of Improved and Effective Oic Drugs
4.6. Restraints
4.6.1. Research On Pain and Next Generation Analgesics
4.6.2. Side Effects of Oic Drugs
4.6.3. Unawareness and Ignorance Among Patients
4.7. Opportunity
4.7.1. Rising Demand For Oic Drugs From Apac Market
4.7.2. Increasing Use of Opioids
4.8. Challenges
4.8.1. Large Number of Considerations While Using Opioids
5. Asia Pacific Oic Drug Market By Drug Type 2017-2025 ($ Million)
5.1. Overview
5.1.1. Methyl Naltrexone Bromide
5.1.2. Lubiprostone
5.1.3. Naloxegol
5.2. Pipeline Drug Analysis: Phase 3: Naldemedine (Year of Launch To 2022 $ Million)
5.3. Pipeline Drug Analysis: Phase 2: Alvimopan, Dolcanatide (Qualitative Information)
5.4. Pipeline Drug Analysis: Phase 3: Elobixibat (Year of Launch To 2022 $ Million)
6. Asia Pacific Cic Drugs Market By Prescription Type 2017-2025 ($ Million)
6.1. Prescribed Drugs
6.1.1. Branded
6.1.2. Generic
6.2. Over the Counter Drugs
7. Key Analytics
7.1. Porters Five Force Model
7.1.1. Intensity of Competitive Rivalryompetition Among The
7.1.2. Bargaining Power of Suppliers
7.1.3. Bargaining Power of Buyers
7.1.4. Threat of Substitute Products
7.1.5. Threat of New Entrants
7.2. Vendor Landscape
7.3. Opportunity Matrix
8. Asia Pacific Oic Drugs Market By Countries 2017-2025 ($ Million)
8.1. China
8.2. Japan
8.3. Rest of Asia Pacific
9. Company Profile
9.1. Ironwood Pharmaceuticals Inc
9.1.1. Overview
9.1.2. Product Portfolio
9.1.3. Strategic Moves
9.1.4. Scot Analysis
9.2. Daiichi Sankyo Co Ltd
9.2.1. Overview
9.2.2. Product Portfolio
9.2.3. Strategic Moves
9.2.4. Scot Analysis
9.3. Pfizer
9.3.1. Overview
9.3.2. Product Portfolio
9.3.3. Strategic Moves
9.3.4. Scot Analysis
9.4. Progenics Pharmaceuticals Inc
9.4.1. Overview
9.4.2. Strategic Moves
9.4.3. Scot Analysis
9.5. Shionogi & Co., Ltd.
9.5.1. Overview
9.5.2. Product Portfolio
9.5.3. Strategic Moves
9.5.4. Scot Analysis
9.6. Allergan Plc
9.6.1. Overview
9.6.2. Product Portfolio
9.6.3. Strategic Moves
9.6.4. Scot Analysis
9.7. Nektar Therapeutics
9.7.1. Overview
9.7.2. Product Portfolio
9.7.3. Strategic Moves
9.7.4. Scot Analysis
9.8. Purdue Pharma L.P.
9.8.1. Overview
9.8.2. Product Portfolio
9.8.3. Strategic Moves
9.8.4. Scot Analysis
9.9. S.L.A. Pharma Ag
9.9.1. Overview
9.9.2. Product Portfolio
9.9.3. Scot Analysis
9.10. Mundipharma International Limited
9.10.1. Overview
9.10.2. Product Portfolio
9.10.3. Strategic Moves
9.10.4. Scot Analysis
9.11. Ono Pharmaceutical Co., Ltd.
9.11.1. Overview
9.11.2. Product Portfolio
9.11.3. Strategic Moves
9.11.4. Scot Analysis
9.12. Takeda Pharmaceutical Company Limited
9.12.1. Overview
9.12.2. Product Portfolio
9.12.3. Strategic Moves
9.12.4. Scot Analysis
9.13. Theravance Biopharma Inc
9.13.1. Overview
9.13.2. Product Portfolio
9.13.3. Strategic Moves
9.13.4. Scot Analysis
9.14. Valeant Pharmaceuticals International
9.14.1. Overview
9.14.2. Product Portfolio
9.14.3. Strategic Moves
9.14.4. Scot Analysis
9.15. Cosmo Pharmaceuticals Sa
9.15.1. Overview
9.15.2. Product Portfolio
9.15.3. Strategic Moves
9.15.4. Scot Analysis
9.16. Daewoong Pharmaceutical Co., Ltd.
9.16.1. Overview
9.16.2. Product Portfolio
9.16.3. Strategic Moves
9.16.4. Scot Analysis
9.17. C.B. Fleet Company, Inc.
9.17.1. Overview
9.17.2. Product Portfolio
9.17.3. Strategic Moves
9.17.4. Scot Analysis

List of Tables

Table 1 Asia Pacific Oic Drug Market By Countries 2017-2025 ($ Million)
Table 2 Pharmacological Approaches To Treat Opioid Induced Constipation
Table 3 Laxatives Used For Opioid Induced Constipation
Table 4 Side Effects of Using Laxatives
Table 5 Patients Unfit For Intake of Opioids
Table 6 Asia Pacific Oic Drug Market By Drug Type, 2017-2025 ($ Million)
Table 7 Product Profile (Methyl Naltrexone Bromide)
Table 8 Product Profile (Lubiprostone)
Table 9 Product Profile (Naloxegol)
Table 10 Pipeline Product Profile (Naldemedine)
Table 11 Pipeline Product Profile (Alvimopan, Dolcanatide)
Table 12 Pipeline Product Profile (Elobixibat)
Table 13 Asia Pacific Oic Drug Market By Prescription Type 2017-2025 ($ Million)
Table 14 Product Profile (Lubiprostone)
Table 15 Asia Pacific Prescribed Oic Drugs Market 2017-2025($ Million)
Table 16 Product Profile (Methyl Naltrexone Bromide)
Table 17 Product Profile (Metamucil)
Table 18 Product Profile (Bisacodyl)
Table 19 Asia Pacific Oic Drug Market By Countries 2017-2025 ($ Million)

List of Figures

Figure 1 Asia Pacific Oic Drugs Market 2017-2025 ($ Million)
Figure 2 Asia Pacific Oic Drug Market By Drug Type 2016 and 2025 (%)
Figure 3 Asia Pacific Oic Drug Market By Prescription Type 2016 (%)
Figure 4 Increasing Number of Opioid Prescription ($ Million)
Figure 5 Reasons For the Growth of Opioid Market.
Figure 6 Common Side Effects of Movantik
Figure 7 Major Usage of Opioids
Figure 8 Considerations Taken While the Opioid Usage
Figure 9 Asia Pacific Methyl Naltrexone Bromide Oic Drug Market 2017-2025 ($ Million)
Figure 10 Asia Pacific Lubiprostone Oic Drug Market 2017-2025 ($Million)
Figure 11 Asia Pacific Naloxegol Oic Drug Market 2017-2025 ($ Million)
Figure 12 Asia Pacific Prescribed Oic Drug Market 2017-2025 ($ Million)
Figure 13 Asia Pacific Prescribed Branded Oic Drug Market 2017-2025 ($ Million)
Figure 14 Asia Pacific Prescribed Generic Oic Drug Market 2017-2025 ($ Million)
Figure 15 Asia Pacific Over the Counter Oic Drug Market 2017-2025 ($ Million)
Figure 16 Asia Pacific Oic Drug Market 2017-2025 ($ Million)
Figure 17 China Oic Drug Market 2017-2025 ($ Million)
Figure 18 Pharmaceuticals Market Sales Across the Globe (%)
Figure 19 Japan Oic Drug Market 2017-2025 ($ Million)
Figure 20 Rest of Apac Oic Drug Market 2017-2025 ($ Million)
  • Global Gastrointestinal Drugs Market Size, Status and Forecast 2025
    Published: 10-Jan-2018        Price: US 3300 Onwards        Pages: 92
    This report studies the global Gastrointestinal Drugs market, analyzes and researches the Gastrointestinal Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Abbott Laboratories - Allergan - AstraZeneca - Bayer - Boehringer Ingelheim - GlaxoSmithKline - Janssen Biotech - Sanofi - Takeda Pharmaceutical - Valeant Phar......
  • Global Anti Peptic Ulcer Drugs Market Size, Status and Forecast 2025
    Published: 10-Jan-2018        Price: US 3300 Onwards        Pages: 104
    This report studies the global Anti Peptic Ulcer Drugs market, analyzes and researches the Anti Peptic Ulcer Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Eisai - Daewoong Pharmaceutical - Takeda Pharmaceutical - HeliCure - AstraZeneca - Ore Pharmaceuticals - Sihuan Pharmaceutical - GlaxoSmithKline - Pfizer - A......
  • Global Irritable Bowel Syndrome (IBS) Market Research Report 2011-2023
    Published: 04-Jan-2018        Price: US 1870 Onwards        Pages: 84
    Summary Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled internat......
  • Global Laxatives Market Professional Survey Report 2017
    Published: 04-Jan-2018        Price: US 3500 Onwards        Pages: 100
    This report studies Laxatives in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - AstraZeneca plc - Boehringer Ingelheim GmbH - Bayer AG - GlaxoSmithKline......
  • Global Laxatives Market Professional Survey Report 2018
    Published: 01-Jan-2018        Price: US 3500 Onwards        Pages: 100
    This report studies Laxatives in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - AstraZeneca plc - Boehringer Ingelheim GmbH - Bayer AG - GlaxoSmithKline......
  • Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 80
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape. Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, asci......
  • Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 44
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Exocrine Pancreatic Insufficiency - Pipeline Review, H2 2017, provides an overview of the Exocrine Pancreatic Insufficiency (Gastrointestinal) pipeline landscape. Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or maldigestion. Symptoms include diarrhea, loose, oily stools with......
  • Short Bowel Syndrome - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 54
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Pipeline Review, H2 2017, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape. Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of shor......
  • Peptic Ulcers - Pipeline Review, H2 2017
    Published: 29-Dec-2017        Price: US 2000 Onwards        Pages: 54
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers - Pipeline Review, H2 2017, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape. Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatme......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs